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ABSTRACT
Background: Vitamin D is a likely candidate for treatment as its immune modulating 
characteristics have effects on coronavirus disease 2019 (COVID-19) patients. It was  sought 
herein, to summarize the studies published to date regarding the vitamin D supplementation to
treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients.
Methods: A systematic review and meta-analysis were performed following Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The 
primary outcome were 14-day and in-hospital mortality reported as an odds ratio (OR) with 
the associated 95% confidence interval (CI).
Results: Eight articles were included in the review with a combined total of 2,322 individual 
patients, 786 in the vitamin D supplementation group and 1,536 in the control group. The use 
of vitamin D compared to the group without vitamin D supplementation was associated with a
lower 14-day mortality (18.8% vs. 31.3%, respectively; OR = 0.51; 95% CI: 0.12–2.19; p = 
0.36), a lower in-hospital mortality (5.6% vs. 16.1%; OR = 0.56; 95% CI: 0.23–1.37; I2 = 
74%; p = 0.20), the rarer intensive care unit admission (6.4% vs. 23.4%; OR = 0.19; 95% CI: 
0.06–0.54; I2 = 77%; p = 0.002) as well as rarer mechanical ventilation (6.5% vs. 18.9%; OR 
= 0.36; 95% CI: 0.16–0.80; I2 = 0.48; p = 0.01).
Conclusions: Vitamin D supplementation in SARS-CoV-2 positive patients has the potential 
to positively impact patients with both mild and severe symptoms. As several high-quality 
randomized control studies have demonstrated a benefit in hospital mortality, vitamin D 
should be considered a supplemental therapy of strong interest. Should vitamin D prove to 
reduce hospitalization rates and symptoms outside of the hospital setting, the cost and benefit 
to global pandemic mitigation efforts would be substantial. 
Key words: COVID-19, SARS-CoV-2, vitamin D, calciferol, systematic review, meta-
analysis
INTRODUCTION
In March of 2020, the respiratory disease caused by the novel severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) — coronavirus disease 2019 (COVID-19) was 
declared a worldwide pandemic by the World Health Organization. Since then, COVID-19 
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has infected hundreds of millions of people and pushed hospital systems to the brink of 
collapse. Now, more infectious variants of COVID-19 are threatening to cause surges in 
hospitalizations and again put pressure on hospitals systems [1]. As the World Health 
Organization (WHO) has issued masking, social distancing, vaccination and other 
preventative measures, some countries have even required their citizens to wear N95 
respirators in public, as this has been found to dramatically reduce the risk of getting infected 
by SARS-CoV-2 [2–4]. While these measures serve as a model for what can be done, this 
measure is likely to be impractical for many countries and governments to implement and 
enforce. As the immediate goal of these interventions has been to decrease hospitalizations, 
identifying a biologically active agent that could reduce or shorten hospitalizations, limit 
severity of disease, or alleviate symptoms would be similarly important [5]. As the vast 
majority of hospitalizations for COVID-19 are due to acute respiratory symptoms leading to 
acute respiratory distress syndrome (ARDS) and respiratory failure [6–8], known immunomo 
dulating candidates that interact with respiratory monocytes are of particular interest [9]. 
Vitamin D is likely the best studied candidate as its immune modulating characteristics and 
effects on pulmonary parenchyma have been well documented [10]. Studies have also 
indicated that there is a correlation between the susceptibility to COVID-19 and lower vitamin
D levels [11]. Additionally, the incidence of vitamin D toxicity is almost non-existent, and this
over-the-counter supplement has been shown to specifically stimulate type II pneumocytes 
[12], which are a prime target of the SARS-CoV-2 virus [13]. This meta-analysis was 
conducted  in order to investigate the possibility of adding vitamin D supplementation to the 
existing recommended COVID-19 prevention and mitigation strategies.
METHODS
The present study involved a systematic literature review and meta-analysis of the 
impact of vitamin D supplementation in SARS-CoV-2 positive patients. The focus was on 
measuring the impact this intervention has had on mortality outcomes according to the 
Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) statement 
[14]. 
Search methods
Applying a predetermined search strategy, two independent reviewers (L.S. and M.P.) 
searched PubMed, EMBASE, Web of Science, Cochrane Collaboration Databases and Scopus
electronic databases from databases inception till July 10th 2021.The search was performed 
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using the following terms: “vitamin D” OR “25-hydroxyvitamin D” OR “calcifediol” AND 
“SARS-CoV-2” OR “COVID-19”. 
Inclusion and exclusion criteria
Studies included in this meta-analysis met the following PICOS criteria: (1) 
PARTICIPANTS; patients > 18 years of age with SARS-CoV-2 positive result, (2) 
INTERVENTION; vitamin D supplementation, (3) COMPARISON; non-vitamin D 
supplementation, (4) OUTCOMES; detailed information for mortality, (5) STUDY DESIGN; 
randomized controlled trials and observational studies. Excluded reviews were simulation 
trials, animal studies, letters, conference papers and case studies. Studies were also excluded 
if the full paper was not available in English.
Data extraction
Two independent reviewers (L.S. and M.P.) performed data extraction. All 
disagreements were resolved by referral to a third author (F.C.) as necessary. From all eligible 
studies, extracted the following information: the name of the first author, year of publication, 
country of research, study design, patient characteristics, and mortality characteristics. Data 
from included studies were recorded using a Microsoft Excel (Microsoft Corporation, 
Redmond, WA, USA) specific report form. When data about the primary outcomes were 
missing, contacting the corresponding author of the original study was planned.
Outcomes 
Primary end points were 14-day and in-hospital mortality. Secondary end points were 
intensive care unit (ICU) admission, need of mechanical ventilation, radiological 
improvement and secondary infection incidence. 
Assessment for risk of bias
The risk of bias (RoB) of the included studies was independently assessed by all three 
authors (L.S., K.B. and A.G.) according to the Cochrane risk-of-bias tool for randomized 
trials (RoB 2 tool) and the Risk of Bias In Non-randomized Studies — of the Interventions 
(ROBINS-I). All disagreements were resolved by referral to the third author (M.J.J.) if 
necessary. The overall RoB 2 and ROBINS-I judgment at domain and study level was 
attributed according to the criteria specified in the ROBVIS tool.
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Statistical analysis
All analyses were performed with the Review Manager software version 5.4 (Nordic 
Cochrane Center, Cochrane Collaboration), and Stata software, version 15.0 (College Station, 
TX, USA). The significance level for all statistical tests was p < 0.05 (two-tailed). For 
dichotomous data, odds ratios (ORs) were used as the effect measure with 95% confidence 
intervals (CIs) and for continuous data mean differences (MDs) were used with 95% CI. 
When the continuous outcome was reported in a study as median, range, and interquartile 
range, estimated means and standard deviations were used using the formula described by 
Hozo et al. [15]. For meta-analysis the random effects model (assuming a distribution of 
effects across studies) was used to weigh estimates of studies in proportion to their 
significance [16]. Heterogeneity was interpreted as not observed when I2 = 0%, low when I2 =
25%, medium when I2 = 50% and high when I2 = 75%.
RESULTS
Search results and study selection
The systematic research, selection and reasons for exclusion are summarized in Figure
1. The literature search yielded 3,612 articles. After the removal of duplicated articles, 1,558 
were included in the analysis. After excluding articles based on predetermined criteria, 8 
articles were included in the review with a combined total of 2,322 individual patients, 786 in 
the vitamin D supplementation group and 1,536 in the control group. These studies originated 
in Spain (n = 4), France (n = 1), Italy (n = 1), Brazil (n = 1) and Singapore (n = 1). Of those, 2
articles were randomized clinical trials [17, 18], and 5 of them were non-randomized trials 
[19–24]. Mean age of COVID-19 patients treated with vitamin D was 62 (15.2) years 
compared to 64.8 (15.4) years for COVID-19 patients treated without vitamin D (MD = –
0.29; 95% CI: –2.33 to 1.74; I2 = 78%; p = 0.78; Suppl. Table 1). Detailed characteristics of 
the studies included in the meta-analysis are presented in Table 1.
Assessment of risk of bias
The detailed methodological description and risk of bias can be found in Figure 2. The
risk of bias judgements summary is presented in Figure 3. In both randomized trials, overall 
risk of bias was rated as low. In the non-randomized trial two of them were rated as low, and 
three as moderate risk of bias. 
Meta-analysis outcomes
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Detailed characteristics of the meta-analysis outcomes are presented in Table 2. 14-day
mortality was reported in only 1 study and was 18.8% for patients with vitamin D 
supplementation compared to 31.3% for the group without vitamin D supplementation (OR = 
0.51; 95% CI: 0.12–2.19; p = 0.36). Seven studies stated in-hospital mortality. Pooled analysis
of in-hospital mortality in the vitamin D vs. non-vitamin D groups show a significant 
difference in mortality rate, 5.6% vs. 16.1%, respectively (OR = 0.56; 95% CI: 0.23–1.37; I2 =
74%; p = 0.20). 
The need for ICU care was statistically lower in the group in which vitamin D was 
administered orally compared to the control group without vitamin D (6.4% vs. 23.4%; OR = 
0.19; 95% CI: 0.06–0.54; I2 = 77%; p = 0.002). 
The implementation of vitamin D supplementation in patients with COVID-19 
compared to patients who did not receive vitamin D was associated with less frequent use of 
mechanical ventilation (6.5% vs. 18.9%; OR = 0.36; 95% CI: 0.16–0.80; I2 = 0.48; p = 0.01). 
The use of vitamin D was also associated with radiological improvement (10.5% vs. 
28.4%; OR = 0.30; 95% CI: 0.07–1.32; p = 0.11) and secondary infection incidence (10.5% 
vs. 22.3%; OR = 0.41; 95% CI: 0.09–1.84; p = 0.24).
DISCUSSION
Though global vaccination against the SARS-CoV-2 virus has been ongoing since late 
2020 and the various vaccines continue to be effective at preventing hospitalizations [25], 
more infectious variants of SARS-CoV-2 are fueling a rebound in infections among the 
unvaccinated [26]. As most countries will not achieve herd immunity from vaccination efforts
until well into 2022, COVID-19 will likely continue to occupy hospital systems in countries 
all over the world [27]. Treatment for hospitalized COVID-19 patients will also limit access to
essential medical services for people suffering from chronic and degenerative diseases [28]. 
As a consequence, research into potential therapeutic agents such as azithromycin and 
chloroquine have made headlines [29, 30], however these strategies proved futile and even 
dangerous [31, 32]. Additionally, the use of Lopinavir, Ritonavir, Remdesivir, Oseltamivir, 
Ribavirin to treat COVID-19 also proved not to be effective [33, 34]. 
At this time, vitamin D, which has immunomodulating characteristics and has been 
shown to be associated with better outcomes in upper respiratory tract infections, should be a 
candidate of interest in mitigating COVID-19 [35, 36]. This inexpensive and readily available 
supplement could be rapidly and widely implemented with minimal risk of detriment to the 
general public. The implementation of which could result in decreased ICU admissions that 
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could reduce the number of occupied ICU beds and result in better clinical outcomes [36]. In 
one randomized control ICU study, supplemental vitamin D administered to COVID-19 
patients, alongside existing therapy, was associated with lower ICU admission and mortality 
[21]. The inclusion criteria included COVID positive patients with clinical and radiological 
findings of ARDS and resulted in a reduction in ICU treatment and a reduction of symptoms. 
It must be noted that the groups did not differ at the baseline with the control group presenting
more often with hypertension while the clinical group was slightly older [37]. 
It has been hypothesized that the benefits of vitamin D in patients suffering from 
ARDS are due to the activation of the vitamin D receptor (VDR) pathway, resulting in a 
decrease of cytokine expression [38], a central cause of rapid deterioration [39]. Additionally, 
vitamin D deficiency in ICU patients is common [40] and may indicate that other 
complications in COVID-19 infections are the result of this deficiency [13]. When a 
combination of vitamin D/magnesium/vitamin B12 were administered the older patients, this 
combination was found to reduce the need for the more advanced procedures without adding 
significant costs [46]. The rationale for this combination lies in the fact that magnesium 
enhances vitamin D activity and plays a pivotal role in the immune system [41, 42]. 
Additionally, vitamin B12 stabilizes the gut microbiota, which has also played a pivotal role 
in a patient’s overall health [43, 44]. These observations are reinforced by other studies where 
vitamin D administered in frail elderly patients was associated with better survival rate and 
less severe COVID-19 course [45].
However, other studies have found that the administration of vitamin D in COVID-19 
patients conveyed no clinical benefit in terms of severity of disease, while also being 
associated with a twofold increase in mortality rate [21]. It can be hypothesized that late 
administration of vitamin D in the presence of severe inflammation could impair the 
metabolism of vitamin D [46], resulting in a buildup of the metabolites. The last study 
included in this review found that the administration of vitamin D administration had no 
effect on the severity of the course of COVID-19 infections [47]. It should be noted that the 
protocol of this trial included the administration of a onetime dose of 200,000 IU of vitamin D
among hospitalized patients with moderate or severe disease. It is not clear if this one dose 
regiment is sufficient as many patients with upper respiratory tract conditions display, e.g., 
asthma, impaired function of the CYP2R1 (vitamin D 25-hydroxylase) [48] which is an 
enzyme that catalyzes the formation of vitamin D3 to 25-hydroxyvitamin D3 (25(OH)D3), 
which reduces the biologically active form of vitamin D.  
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CONCLUSIONS
Vitamin D supplementation in SARS-CoV-2 positive patients has the potential to 
positively impact patients with both mild and severe symptoms. As a number of high-quality 
randomized control studies have demonstrated a benefit in hospital mortality, vitamin D 
should be considered a supplemental therapy of strong interest. At the same time, should 
vitamin D prove to reduce hospitalization rates and symptoms outside of the hospital setting, 
the cost and benefit to global pandemic mitigation efforts would be substantial. It can be 
concluded that further multicenter investigation of vitamin D in SARS-CoV-2 positive 
patients is urgently warranted at this time. 
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Table 1. Characteristics of included studies.
Study Country Study design
Vitamin D supplementation group Non-vitamin D supplementation group
No. Age Sex, male No. Age Sex, male
Alcala-Diaz et 
al., 2021
Spain Retrospective, multicenter cohort study




16 58.4 ± 7 11 (68.8%) 32 64.1 ± 7.9 19 (59.4%)
Castillo et al., 
2020
Spain Parallel pilot randomized open label, 
double- masked clinical study
50 56.8 ± 14.2 27 (54.0%) 26 55.8 ± 15 18 (69.2%)
Cereda et al., 
2021
Italy Cohort observational study
38 68.8 ± 10.6 16 (42.1%) 286 70.5 ± 13.1 141 (49.3%)
Hernández et 
al., 2020
Spain Retrospective case–control study
19 63.5 ± 4.6 7 (36.8%) 197 59.9 ± 3.8 123 (62.4%)
Murai et al., 
2021
Brazil Multicenter, double-blind, randomized,
placebo-controlled study
120 53.1 ± 10.8 70 (58.3%) 120 52.8 ± 9.4 65 (54.2%)
Nogues et al., 
2021
Spain Observational cohort study
447 61.8 ± 15.5 264 (59.1%) 391 62.4 ± 17.2 231 (59.1%)
Tan et al., 2020 Singapore Cohort observational study 17 85.8 ± 1.5 11 (64.7%) 26 88 ± 2.3 15 (57.7%)













Odds ratio 95%CI P-value I2 statistic
Mechanical ventilation 2 9/139 (6.5%) 60/317 (1.9%) 0.38 0.17 to 0.86 0.48 0% 0.02
Radiological worsening 1 2/19 (10.5%) 56/197 (28.4%) 0.30 0.07 to 1.32 NA NA 0.11
Secondary infection 1 2/19 (10.5%) 44/197 (22.3%) 0.41 0.09 to 1.84 NA NA 0.24
Thrombotic events 1 1/19 (5.3%) 10/197 (5.1%) 1.04 0.13 to 8.58 NA NA 0.97




















CI — confidence interval; ICU — intensive care unit; NA — not applicable
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Figure 1. Flow diagram showing stages of the database search and study selection as per 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Figure 2. A plot of the distribution of review authors’ judgements across; randomized (A) and
non-randomized (B) studies for each risk of bias item.
Figure 3. A summary table of review authors' judgements for each risk of bias item for each 
randomized (A) and non-randomized (B) study.
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